You are here: Industry Insights > InnoCare

News List

InnoCare Appoints Xin Fu as Chief Financial Officer PharmaSources
December 18, 2023
InnoCare Pharma, announced today that the Company appointed Mr. Xin Fu, who has extensive finance-related experience, as the Chief Financial Officer.
InnoCare Announces Inclusion of Orelabrutinib’s New Indication in China National Reimbursement Drug List 2023 PharmaSources
December 14, 2023
InnoCare Pharma announced today the inclusion of new indication of BTK inhibitor orelabrutinib in the updated National Reimbursement Drug List 2023.
Latest Data of InnoCare’s Oncology Pipelines Presented at the 65th Annual Meeting of ASH PharmaSources
December 11, 2023
InnoCare Pharma announced today that the latest data from InnoCare's oncology studies were presented at the 65th American Society of Hematology (ASH) Annual Meeting.
Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology PharmaSources
September 13, 2023
American Journal of Hematology recently published the study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in patients with relapsed or refractory (r/r) Marginal Zone Lymphoma (MZL).
InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China PharmaSources
July 05, 2023
On July 5, 2023,InnoCare Pharma announced the first psoriasis patient has been dosed in clinical trial of the Company’s TYK2 JH2 allosteric inhibitor ICP-488 in China.
Latest Data of InnoCare’s Orelabrutinib Presented at the 17th International Conference on Malignant Lymphoma (ICML) PharmaSources
June 16, 2023
On June 16, 2023,InnoCare Pharma, a leading biopharmaceutical company, today announced the latest clinical data of its Bruton Tyrosine Kinase inhibitor orelabrutinib at the 17th International Conference on Malignant Lymphoma.
Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2023 Hybrid Congress PharmaSources
June 12, 2023
On June 12, 2023,Data of InnoCare’s robust pipelines were presented at the European Hematology Association 2023 Hybrid Congress.
InnoCare Announces Orelabrutinib Becomes the First and the Only BTK Inhibitor Approved in China for the Treatment of R/R MZL PharmaSources
April 20, 2023
April 20, 2023，InnoCare Pharma announced today that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration in the treatment of patients with relapsed/refractory marginal zone lymphoma .
Data of InnoCare’s Robust Oncology Pipelines Presented at the 2023 AACR Annual Meeting PharmaSources
April 18, 2023
April 18, 2023，Data of InnoCare’s robust oncology pipelines were presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
InnoCare Announces First Subject Dosed in Clinical Trial of Novel Targeted Protein Degrader ICP-490 in China PharmaSources
April 04, 2023
April 4, 2023，InnoCare Pharma announced today that the first subject has been dosed in clinical trial of the Company’s novel targeted protein degrader ICP-490 in China.

Previous page 1 2 3 4 5 6 Next page